Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | KAT2A | Q92830 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446281 | 0.83 | KAT2A (0.33) | HCAR2KAT2A | |
| SCHEMBL16585834 | 0.76 | — | — | |
| SCHEMBL3407152 | 0.76 | — | — | |
| SCHEMBL3103050 | 0.76 | — | — | |
| SCHEMBL2004047 | 0.71 | ARG1 (0.33) | ARG1 | |
| Hydroxyamine SCHEMBL28060008 | 0.71 | — | — | |
| SCHEMBL162651 | 0.69 | — | — | |
| SCHEMBL30381584 | 0.67 | KAT2A (0.34) | KAT2AKMT2A | |
| SCHEMBL30381506 | 0.67 | KAT2A (0.34) | KAT2AKMT2A | |
| SCHEMBL980766 | 0.67 | KAT2A (0.34) | KAT2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816387-B2 | β secretase inhibitor | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090198056-A1 | Beta secretase inhibitor | KISO, YOSHIAKI (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1942101-A1 | SECRETASE INHIBITOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198056-A1 | Beta secretase inhibitor | BACE1, BACE2, APP | HCAR2 2436/4885ARG1 204/4885KAT2A 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.